Beacon BreakingNews - Clinical Trial Supports Revlimid As First-Line Therapy For Myeloma
Celgene, the manufacturer of Revlimid (lenalidomide), announced today positive results from a Phase 3 clinical trial using Revlimid as first-line therapy for newly diagnosed multiple myeloma patients. Results show that Revlimid in combination with melphalan (Alkeran) and prednisone, followed by continuous Revlimid, significantly improved time to tumor progression.
Check back for further coverage on The Myeloma Beacon.
Update: Please see The Myeloma Beacon's full coverage of Revlimid as a first-line therapy for myeloma.
Photo by gtrwndr87 on Flickr – some rights reserved.
Related Articles:
- Nelfinavir Shows Only Limited Success In Overcoming Revlimid Resistance In Multiple Myeloma Patients
- bb2121 Continues To Impress As Potential New Multiple Myeloma Therapy (ASCO 2018)
- Dr. Christoph Driessen On Nelfinavir In The Treatment Of Multiple Myeloma
- U.S. FDA Okays First Clinical Trial Of An Allogeneic CAR T-Cell Therapy For Multiple Myeloma
- Adding Clarithromycin To Velcade-Based Myeloma Treatment Regimen Fails To Increase Efficacy While Markedly Increasing Side Effects
